 | |
| Clinical data | |
|---|---|
| Trade names | Psorcon |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602019 |
| License data |
|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.046.872 |
| Chemical and physical data | |
| Formula | C26H32F2O7 |
| Molar mass | 494.532 g·mol−1 |
| |
  (what is this?) (verify) | |
Diflorasone diacetate is a topical steroid that comes in the form of a cream. It is manufactured by E. Fougera & Co. and is used as an anti-inflammatory and anti-itching agent, like other topical corticosteroids. It is prescribed for psoriasis [1] and atopic dermatitis, among other conditions. With respect to potency, it is regarded as a Class I corticosteroid [of classes I – VII] in the United States. [2]
No long-term animal studies have been done to determine whether diflorasone diacetate could have carcinogenic properties.[ citation needed ]
Little data is available regarding whether diflorasone diacetate would be present in great enough quantities to cause harm to an infant. [3]
